IRMD Q4 2025: 17% Revenue Growth Sets Up $100M+ Run Rate on 3870 Pump Launch
IRadimed’s Q4 capped 18 straight quarters of record revenue, with broad-based product growth and a pivotal new pump launch positioning the company for a step-change in scale. The 3870 MR IV pump rollout, targeting a sizable installed base replacement, underpins management’s confidence in surpassing a $100 million revenue run rate in 2026. Investors should watch the pace of 3870 adoption, margin trajectory, and international regulatory milestones as key levers for valuation re-rating.
Summary
- Replacement Opportunity Drives Inflection: The 3870 pump launch targets thousands of legacy units, setting up multi-year growth.
- Margin Leverage Hinges on Ramp: Gross margins expected to improve as 3870 volumes scale in the second half.
- International Expansion Timeline: Regulatory clearance in Europe and Japan remains a 2026–2027 catalyst.
Business Overview
IRadimed designs and manufactures MRI-compatible medical devices, primarily infusion pump systems (devices for delivering fluids and medications during MRI procedures), patient monitoring systems (vital sign monitors for MRI environments), and disposables (consumables used with these systems). Revenue is generated through capital equipment sales, recurring disposables, service contracts, and a small but growing ferromagnetic detection business. The U.S. market accounted for 81% of Q4 revenue, with the remainder from international sales.
Performance Analysis
Q4 revenue grew 17% year-over-year, reaching $22.7 million and marking the company’s 18th consecutive quarter of record top-line results. Growth was broad-based: MRI-compatible IV pump systems delivered 20% growth, patient monitoring systems rose 7.5%, and disposables revenue increased 18%, reflecting higher device utilization. Gross margin remained robust at 75% for the quarter, with annual margin stable at 77%, indicating IRadimed’s premium pricing power and efficient cost structure.
Operating expenses increased modestly, primarily to support expansion and the 3870 launch, but income from operations and net income both posted double-digit gains. Free cash flow remained strong at $5.5 million in Q4 and $16.5 million for the year, supporting a healthy cash position of $51.2 million. The company’s effective tax rate fell to 17.3% in Q4 due to a year-end true-up, lowering the full-year rate to 20.7%.
- Disposables and Monitoring Outperformed: Higher device utilization and new customer adoption lifted recurring revenue streams.
- Backlog and Inventory Management: Careful balancing of legacy 3860 pump inventory with 3870 ramp mitigates transition risk.
- Operating Leverage Maintained: Growth in gross profit outpaced opex, supporting margin resilience through product transition.
With the 3870 pump launch set to accelerate in Q2 and a significant installed base replacement cycle ahead, IRadimed’s revenue mix and scale are poised for a structural shift in 2026.
Executive Commentary
"The most significant increase comes from the large replacement opportunity, which is the number one driver we see and will deliver a significant step change in revenue, continuing to be our key growth driver for the next several years."
Roger Sussi, President and Chief Executive Officer
"We anticipate that as we get into the second half of the year on those higher volumes, along with... the higher ASP as well, that we would think that we could certainly trend a little bit higher in the second half of the year."
Jack Glenn, Chief Financial Officer
Strategic Positioning
1. 3870 Pump Launch and Installed Base Replacement
IRadimed’s 3870 pump, a next-generation MRI-compatible IV infusion system, is positioned to drive a step-change in revenue by targeting replacement of over 6,400 legacy 3860/3861 pump channels in the U.S. alone. Management expects to add 1,000 incremental channels per year, on top of the historical 1,100 annual run rate, with an average selling price (ASP) premium of 10–14% over the prior model. This replacement cycle, coupled with greenfield sales, is expected to underpin a $50 million annual pump revenue run rate domestically.
2. Margin Expansion Through Scale and Mix
Gross margin stability was maintained through the legacy transition, but management expects margin improvement as 3870 volumes ramp in the second half. The higher ASP and operational efficiency from the new facility should offset initial subscale production costs. Disposables, which carry attractive margins, are also forecast to grow faster as new pump utilization increases.
3. International Expansion and Regulatory Pathway
While the U.S. replacement cycle is the immediate growth engine, international expansion remains a medium-term lever. The 3870 is on track for CE Mark in Europe by late 2026, with Japan approval expected by summer 2027. These milestones will open new markets and extend the replacement opportunity globally.
4. R&D Roadmap for Monitoring Platform
IRadimed has already initiated development of a refreshed MRI monitoring system, targeting a 2028 launch. This pipeline investment signals management’s intent to sustain product leadership and diversify revenue beyond the pump cycle.
Key Considerations
The Q4 print and guidance highlight IRadimed’s transition from a single-product cycle to a multi-year installed base monetization story, with operational discipline and margin resilience as key differentiators.
Key Considerations:
- Scale of Replacement Cycle: The 3870 pump launch directly addresses a large, aging installed base, with a multi-year window for conversion and upsell.
- ASP and Utilization Upside: New pump design and user interface improvements are expected to drive both higher ASPs and greater disposable consumption per site.
- Execution Risk in Transition: Managing 3860 inventory and ensuring a smooth ramp of 3870 production and shipments is critical for near-term results.
- International Regulatory Milestones: Delays in CE Mark or Japan approval could defer the next leg of growth, though U.S. momentum provides a buffer.
- Pipeline Beyond Pumps: The monitoring system refresh for 2028 is already in motion, supporting longer-term product cycle renewal.
Risks
Execution around the 3870 ramp is the central risk, as delays or quality issues could disrupt the replacement cycle and revenue cadence. Margin improvement is predicated on achieving scale in the second half, so any demand shortfall or operational hiccup could pressure profitability. International expansion is subject to regulatory timelines and market adoption, which may slip. Competitive dynamics in MRI-compatible devices, while muted, could intensify if larger players enter the field or pricing comes under pressure.
Forward Outlook
For Q1 and Q2 2026, IRadimed expects revenue to remain steady, driven by continued monitoring growth and fulfillment of 3860 backlog. The major inflection is forecast in the second half as 3870 shipments ramp, with 100–130 channels targeted for initial April deliveries.
- Full-year 2026: Management expects to approach a $100 million revenue run rate, anchored by domestic pump replacement, disposables growth, and stable monitoring sales.
Management highlighted several factors that will shape results:
- Booking strength for 3870 expected to build in Q2 and accelerate in H2 2026
- Gross margin likely to improve with scale and higher ASPs in the back half
Takeaways
IRadimed enters 2026 with a clear catalyst in the 3870 launch, a substantial replacement opportunity, and a path to margin expansion. The quarter’s results validate the company’s execution discipline and set the stage for a multi-year growth cycle.
- Replacement Cycle Upside: The 3870 pump addresses a large, visible installed base, with management targeting a doubling of annual replacement sales and higher ASPs.
- Margin and Cash Flow Leverage: Operational discipline and product mix support robust free cash flow, with margin expansion tied to successful 3870 scaling.
- 2026 Watchpoints: Investors should monitor the pace of 3870 adoption, gross margin trends, and progress on international regulatory approvals as key drivers of upside or risk.
Conclusion
IRadimed’s Q4 and full-year results confirm durable demand and set up a transformative year as the 3870 pump launch moves from pilot to scale. The company’s focus on installed base monetization, disciplined execution, and pipeline renewal position it as a differentiated medtech growth story for 2026 and beyond.
Industry Read-Through
IRadimed’s results underscore the power of installed base replacement cycles in medtech, particularly for niche capital equipment with high switching costs and recurring disposable revenue. The successful transition to next-generation hardware, paired with pricing discipline, offers a blueprint for other device makers seeking to drive step-change growth from legacy fleets. The company’s focus on operational leverage and cash flow, even amid product transitions, highlights the importance of execution and inventory management in medtech. International regulatory timelines remain a gating factor for global expansion, a dynamic relevant to all device manufacturers with aspirations beyond the U.S. market.